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http:WHAT THIS PAPER ADDS
With recent changes in abdominal aortic aneurysm (AAA) epidemiology, the fundamental conditions for AAA
may have changed. Using an up-to-date Markov model this study analyses AAA screening within a setting of
contemporary epidemiology and surgical management, and indicates that one-time screening of 65-year-old
men for AAA remains highly cost-effective and is a clinically relevant health initiative.Objectives: The epidemiology and management of abdominal aortic aneurysms (AAA) has changed signiﬁcantly,
with lower prevalence, increased longevity of patients, increased use of endovascular aneurysm repair (EVAR),
and improved outcome. The clinical and health economic effectiveness of one-time screening of 65-year-old men
was assessed within this context.
Methods: One-time ultrasound screening of 65-year-old men (invited) versus no screening (control) was analysed
in a Markov model. Data on the natural course of AAA (risk of repair and rupture) was based on randomised
controlled trials. Screening detected AAA prevalence (1.7%), surgical management (50% EVAR), repair outcome,
costs, and long-term survival were based on contemporary population-based data. Incremental cost-efﬁciency
ratios (ICER), absolute and relative risk reduction for death from AAA (ARR, RRR), numbers needed to screen
(NNS), and life-years gained were calculated. Annual discounting was 3.5%.
Results: In base case at 13-years follow-up the ICER was V14,706 per incremental quality-adjusted life-year
(QALY); ARR was 15.1 per 10,000 invited, NNS was 530, and QALYs gained were 56.5 per 10,000 invited. RRR was
42% (from 0.36% in control to 0.21% in invited). In a lifetime analysis the ICER of screening decreased to V7,570/
QALY. The parameters with highest impact on the cost-efﬁciency of screening in the sensitivity analysis were the
prevalence of AAA (threshold value <0.5%) and degree of incidental detection in the control cohort.
Conclusions: In the face of recent changes in the management and epidemiology of AAA, screening men for AAA
remains cost-effective and delivers signiﬁcant clinical impact.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In the late 1990s, randomised controlled trials (RCTs), with
the Multicentre Aneurysm Screening Study (MASS) being
the most inﬂuential, demonstrated a cost-effective reduc-
tion in long-term mortality from ruptured abdominal aortic
aneurysm (AAA) with ultrasound-based screening of elderly
men.1e4 Paradoxically, the ensuing implementation of
nationwide AAA screening programmes in Europe5,6 and the
USA7 coincided with signiﬁcant changes in the epidemiology
and management of AAA observed in the last decade, allrresponding author. S. Svensjö, Department of Surgery, Falun County
l, SE-791 82 Falun, Sweden.
il address: sverker.svensjo@ltdalarna.se (S. Svensjö).
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//dx.doi.org/10.1016/j.ejvs.2013.12.023potentially fundamental conditions for the rationality of
AAA screening.
The most notable changes are a signiﬁcantly reduced
prevalence of the disease, likely due to reduced smoking
and improved cardiovascular risk factor management;8e12 a
substantially improved short- and long-term survival after
AAA repair;13 a generally increased longevity in the popu-
lation; and a net increase in elective surgery, mainly owing
to the introduction of EVAR.14,15 Thus, the basis for the
currently implemented AAA screening programmes may be
questioned.
The aim of this study was to determine the current effect
and cost-effectiveness of one-time AAA screening of 65-
year-old men in a Markov model using the best evidence
data from the largest RCT and contemporary population-
based data from original articles.
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Figure 1. The Markov model. Circles represent health states and
boxes represent events. The thin lines with arrows depict possible
pathways for individuals in the model. A curved arrow represents
the possibility of an individual remaining in a health state for
consecutive cycles. Note. AAA ¼ abdominal aortic aneurysm;
EVAR ¼ endovascular aneurysm repair; OR ¼ open repair.
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Model strategies
Two hypothetical cohorts of 65-year-old men were assigned
to either a strategy of invitation to one-time AAA screening
with ultrasound (invited), or a strategy of no screening
(control) where AAA management was based on incidental
detection. An AAA was deﬁned as a maximum infrarenal
aortic diameter of 30 mm or more.Model structure
A Markov model with ﬁve exclusive health states (Fig. 1)
was constructed. At the start, individuals from each cohort
are assigned to the AAA state or no AAA state based on
the prevalence of AAA. The simulation progresses in cycles
of 1 year. The effect and cost of each strategy is sum-
marised after a set number of cycles. In addition, in a
Monte Carlo analysis, the number of key events, such asrupture, elective surgery, and death from varying causes,
were recorded for the purpose of outcome calculation and
subsequent validation of the model. Monte Carlo analysis
was set to 1,000,000 individuals in each cohort. The model
was developed in the TreeAge Pro 2012 Healthcare soft-
ware package (TreeAge Software, Williamstown, MA,
USA).
Parameters and data sources
The parameters are summarised in Table 1. The screening
detected prevalence (1.7%) in the base case (standard
scenario or default setting) in the model was based on a
recent population-based prevalence study in Middle Swe-
den.8 The time-dependent probability of an AAA progress-
ing to rupture or elective surgery in the respective cohort
was based on the MASS study, which reported in detail on
these parameters at 4, 7, 10, and 13 years,1,16e18 corrected
for difference in prevalence between MASS and recent
Swedish data.
Based on extensive Swedvasc registry data19 on the age
distribution of AAA repairs and on the survival pattern of
individuals with AAA it was assumed that no repairs for
intact AAA occurred after the age of 90 years.
Age-speciﬁc operative (30-day) mortality after elective
and rupture repair by open repair (OR) and endovascular
aneurysm repair (EVAR) was retrieved from the Swedvasc19
registry for the years 2002e2010. General population age-
dependent all-cause mortalities were based on contempo-
rary population statistics from Statistics Sweden.20 Data on
contemporary gender-speciﬁc long-term survival after AAA
repair in Sweden21 was used for modelling long-term sur-
vival for all individuals with AAA, where the 5-year survival
rate of an individual with an AAA or surviving elective AAA
repair was estimated to be 95% in relation to the general
population and to be 90% for an individual surviving surgery
for a ruptured AAA.
Health state utilities, the basis for calculation of effect in
quality-adjusted life-years (QALYs), were age-dependent,
and retrieved from a gender- and age-speciﬁc Swedish
EQ-5D health-related quality of life population estimate.22
A number of parameters were included in a sensitivity
analysis, and the ranges tested are shown in Table 1. The
proportion of incidentally detected and repaired AAAs in
the control cohort compared with the screened cohort in
MASS at 4 and 13 years was estimated at 25% and 42%,
respectively, in accordance with a suggested method.23 A
corresponding contemporary proportion of incidental
detection and repair of 39% at 4-year follow-up was esti-
mated from Swedvasc, based on a comparison of 4 years
preceding the Swedish screening initiative and 4 years post-
screening for 65-year-old men.
More details on parameters are provided in the
Supplementary material.
Costs
All costs (Table 2) are taken from the perspective of a
health service provider. Using speciﬁc gross domestic
Table 1. Parameters in the model.
Parameters in the model Base case Range tested in sensitivity analysis References
Prevalence, 65-y-old men (%) 1.7 0.1e4.0 8,12,46
Attendance 80% 8,12,46
30-d mortality, age-dependent for ages 65e85 yþ
OR for intact AAA 1.62e7.69% 19
EVAR for intact AAA 0.85e2.38% 19
OR for ruptured AAA 17.8e52.9% 19
EVAR for ruptured AAA 7.4e46.2% 19
Proportion EVAR/OR repair for intact AAA 50% 19
Proportion EVAR/OR for repair of ruptured AAA 10% 19
Time-dependent rates at 1e4, 5e7, 8e10, 11e13, and 25 y
Annual risk of surgery for intact AAA in invited
cohort
4.89%, 2.75%, 1.81%, 1.38%, 0.00% 1,16e19
Annual risk of surgery for intact AAA in control
cohort
1.46%, 1.56%, 1.02%, 1.46%, 0.00% 1,16e19
Time-dependent rates at 1e4, 5e7, 8e10, 11e13, and 30 y
Annual risk of rupture in invited cohort 1.01%, 1.00%, 1.18%, 1.46%, 0% 1,16e18
Annual risk of rupture in control cohort 1.97%, 2.29%, 2.33%, 2.03%, 0% 1,16e18
Probability of surgery in case of rupture, invited 23.69% Up to 2 1,16e18
Probability of surgery in case of rupture, control 31.17% Up to 2 1e4
Population mortality Life-tables, ages 65e105 y 20,47
Relative non-AAA-related mortality of individual
with AAA, and individual post-surgery for rupture
1.11, 1.19 1.0e3.0 21,48e52
Relative risk reduction in non-AAA-related
mortality in invited group
0.53% 1
Proportion of incidentally detected and repaired
AAAs in control cohort at 13 years compared with
screened cohort
42% 25e85% 1,23
Utility, 65e69, 70e79, 80þ y 0.83, 0.81, 0.74 22
Note. OR ¼ open repair; AAA ¼ abdominal aortic aneurysm; EVAR ¼ endovascular aneurysm repair.
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gion,24 all costs were adjusted to the value for 2012 and
converted to Euros (V) with the mean exchange currency
for 2012 (1V:£0.81:$1.28:SEK8.73).25 Screening costs were
based on actual total costs in ongoing screening pro-
grammes in Middle Sweden. The cost of surgery for intact
AAA and subsequent postoperative management was
retrieved from a recent cost analysis study from Sweden.26
Data from key references determined the ranges of cost
tested in the sensitivity analysis. The base case cost of
surgery for rupture was calculated as a multiple of the cost
of surgery for intact AAA based on MASS data at 10 years.
Cost and effect were discounted at 3.5% annually, in line
with UK National Institutes of Clinical Excellence (NICE)
recommendations.27Outcome
Measures of outcome in the model were effect in life-years
(LY) and QALYs, incremental cost efﬁciency ratio (ICER) in V
per LY gained (LYG) and per QALY gained, absolute risk
reduction (ARR) for AAA-related death per 10,000 invited,
numbers needed to screen (NNS) to prevent one AAA-
related death (based on 1/ARR and adjusted for an atten-
dance rate of 80%), relative risk reduction (RRR) for AAA-
related death, and LYG per prevented death from AAA.Results were determined at 10, 13, and 40 (lifetime) years
of follow-up.Validation
The outcome of the model was validated against the
outcomes observed in the MASS study using model input
reﬂecting key parameters of the MASS study: a starting
age of 69 years (mean age at inclusion in MASS), preva-
lence of 4.9%, 13% proportion of EVAR, population death
rates for men in the UK from 1998 and onward, and
application of a multiplier to peri-operative mortality
reﬂecting the difference in mortality between Swedish
65e74-year-old men 2002e2010 in the Swedvasc registry
and the MASS study. Key events were generated by Monte
Carlo analysis.
RESULTS
Base case analysis
At 13 years, the RRR for death from AAA was 42% (absolute
risk of 0.36% in the control cohort and 0.21% in the invited
cohort), the ICERs, in V/QALY gained, and V/LY gained in
the invited cohort, were V14,706 and V11,558 respectively.
The ARR for death from AAA was 15.1/10,000 invited, 530
needed to be screened to prevent one death from AAA, and
Table 2. Costs in the model.
V Range tested Source
Invitation 5.39 Actual costs from Swedish screening programme
Ultrasound screening exam 16.45 V10e40 Actual costs from Swedish screening programme, MASS16
Surveillance per year 117.80 V50e250 Actual costs from Swedish screening programme, MASS16
Elective surgery
OR 30,099 0.5 to 2.0 Mani et al.,26 Brown et al.,53 MASS,16 OVER54
OR, postoperative, total per casea 5,516 Mani et al.,26 Brown et al.,53 MASS,16 OVER54
EVAR 24,493 0.5 to 2.0 Mani et al.,26 Brown et al.,53 MASS,16 OVER54
EVAR, postoperative, total per casea 5,265 Mani et al.,26 Brown et al.,53 MASS,16 OVER54
Surgery for rupture
(cost  elective surgery) 1.62 1.3e3.0 MASS16
Note. All costs have been adjusted to 2012 value. OR ¼ open repair; EVAR ¼ endovascular aneurysm repair.
a Mean follow-up ¼ 5.4 years.
360 S. Svensjö et al.4.8 LY were gained for each AAA death prevented. A sum-
mary of the base case analysis, predicted for each length of
follow-up, is presented in Table 3. Relevant key events in
the model’s base case, together with corresponding MASS
results, are shown in Fig. 2.Sensitivity analysis
The results of the sensitivity analysis at 13 years are pre-
sented in Table 4. In Fig. 3, the ICER per QALY gained is
plotted against the range of prevalence rates tested for
various degrees of incidental detection and repair in the
control cohort.Validation
The validation procedure resulted in output highly
congruent with the MASS results, with no signiﬁcant dif-
ferences in predicted number of key events in the model
cohorts versus the observed key events in MASS at 13-year
follow-up.
DISCUSSION
In this Markov model simulation study, using the thresholds
of UK’s NICE27 (£20,000/V25,000), one-time screening of
65-year-old men for AAA was cost-effective in a context of
contemporary AAA epidemiology and management. In aTable 3. Base case effect and cost-effectiveness according to length o
10-y follo
Effect, life-years per person, invited/(control) 7.9072/(7
ICER, V/life-year gained in invited cohort 18,552
Life-years gained per 10,000 invited cohort 46.7
Effect, QALYs per person, invited/(control) 6.3941/(6
ICER, V/QALY gained in invited cohort 23,265
QALYs gained per 10,000 invited 37.3
ARR, death from AAA per 10,000 invited 13.4
NNS to prevent one death from AAA 597
RRR, death from AAA, % 49.2
Life-years gained for each prevented AAA death 3.5
Note. All effects and costs are discounted at 3.5% annually. ICER ¼ in
ARR ¼ absolute risk reduction; NNS ¼ numbers needed to treat; RRRsensitivity analysis, the prevalence of AAA and the degree of
incidentally detected AAAs in the population were the most
important parameters affecting the impact and cost-
efﬁciency of the screening programme.Prevalence rate of AAA
A signiﬁcant change in AAA epidemiology is evident based
on recent national and regional screening programmes,
with a diminishing disease occurrence in predominantly
younger age groups.8,10e12 The profound changes in AAA
management and epidemiology are evident when
comparing key parameters of today’s epidemiology with
those at the time of inclusion of patients in the MASS study
(Table 5). A prerequisite for any screening programme is
that the disease screened for is a signiﬁcant health problem.
Although AAA rupture rates are showing signs of
decreasing, AAA appears to remain a signiﬁcant health
problem.14 The decrease in AAA prevalence, owing, to a
great extent to falling smoking rates in Western societies,
has rightfully called the emerging screening programmes
into question.5,7,8,14 In this study, cost-effectiveness for AAA
screening was fairly insensitive to changes in prevalence
down to rates of approximately 0.5% (Fig. 3). As expected,
the absolute risk reduction per 10,000 invited (Tables 3 and
4) was proportionally lower with lower disease prevalence,
but with extended life expectancy and improved AAA repairf follow-up.
w-up 13-y follow-up Lifetime follow-up
.9026) 9.5209/(9.5137) 13.1543/(13.1401)
11,558 5,783
71.9 142.4
.3904) 7.6285/(7.6228) 10.3237/(10.3128)
14,706 7,570
56.5 108.8
15.1 16.4
530 488
42.1 40.2
4.8 8.7
cremental cost-efﬁciency ratio; QALY ¼ quality-adjusted life-year;
¼ relative risk reduction.
Figure 2. Key events and parameters in the base case of the model (65-year-old men) and Multicentre Aneurysm Screening Study (MASS)
(65e74-year-old men), based on 10,000 individuals in each cohort with 13 years of follow-up. (AeC) Corresponding results extracted from
the MASS study are displayed for reference, as reported at 4, 7, 10, and 13 years. All results from the model were based on an abdominal
aortic aneurysm (AAA) prevalence of 1.7%, an attendance of 80% for screening, and a 42% degree of incidental detection and repair in the
control cohort. (A) Accumulated number (n) of intact AAA repairs according to years of follow-up. (B) Accumulated number (n) of ruptures
according to years of follow-up. (C) Patients alive according to years of follow-up. Figures are combined for invited and control cohort. (D)
Number (n) of intact AAAs remaining in the population according to years of follow-up.
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clinically signiﬁcant (8.7 years, in lifetime analysis).
Incidental detection of AAA in the control cohort
Based on MASS data at 4- and 13-year follow-up, the
proportion of incidentally detected and repaired AAAs in
the control cohort (no screening system) was estimated to
be 25% and 42% respectively.23 However, recent data
suggest a possibly higher current degree of incidental
detection in contemporary populations. In the initial phase
of the MASS study, the estimated ratio of known and
repaired AAAs versus previously undetected AAAs was 1:9
(11%), according to the study proﬁle.18 The corresponding
ratio was 1:4 (29%) at the time of the initiation of screening
in Sweden.8 In addition, using Swedvasc data on inciden-
tally detected and repaired AAAs in the time period pre-
ceding the Swedish screening programme compared with
the time period with a screening programme up and
running, a corresponding contemporary 4-year estimate of
39% for 65-year-old men was calculated. This degree of
incidental detection was thus 50% higher than in MASS, but
equal to that in the Western Australian RCT at 4 years.28
Our sensitivity analysis showed that a high degree of inci-
dental detection signiﬁcantly decreases the cost-efﬁciencyand clinical impact of a screening system introduced into
that population, but this effect was prominent in base case
only if the degree was approximately 75% at 13 years
follow-up, corresponding to roughly a 100% increase in
incidental detection compared with MASS (Fig. 3). There is
an interaction between the two main parameters with in-
ﬂuence on cost-effectiveness. If, for instance, both the
incidental detection increases above 65% and the preva-
lence decreases below 0.8%, cost-effectiveness is lost
(Fig. 3).
Willingness-to-pay thresholds as indicators of how much
a society would invest in a new treatment in V per QALYs
gained are most likely subject to international variation.
However, a commonly cited reference threshold is that of
NICE,27 where an ICER <V25,000 per incremental QALY is
normally seen as an effective use of healthcare resources,
and ICERs exceeding this are subject to increased scrutiny.
In guidelines for cancer treatment published in 2007 by the
National Board of Health and Welfare in Sweden, an ICER of
<V11,680/QALY gained was deemed low (V11,681e
V58,411 ¼ medium; V58,412eV116,822 ¼ high;
>V116,822 ¼ very high).29 At present, in relation to the
suggested ICER thresholds, one-time AAA screening of 65-
year-old men appears to be highly cost-effective.
Table 4. Sensitivity analysis of model parameters and costs. Follow-up is 13 years.
Parameter/cost ICER V/
life-year
gained
in invited
cohort
Life-years
gained per
10,000
invited
cohort
ICER V/
QALY gained
in invited
cohort
QALYs gained
per 10,000
invited
ARR death from
AAA per
10,000
invited
Base case V11,558 71.9 V14,706 56.5 15.1
Prevalence
Base case 1.7%
Lower limit 0.1% V34,474 6.5 V49,914 5.1 0.7
Higher limit 4% V10,271 165.9 V13,068 130.4 34.1
Degree of incidental detection and repair in control cohort
Base case 42%
Lower limit 25% V10,515 98.3 V13,380 77.3 20.6
Higher limit 85% V46,300 7.3 V58,987 5.8 0.4
Probability of surgery in case of rupture (invited/control)
Base case, invited/control 24%/31%
Lower limit 1.5 V11,578 56.2 V14,739 44.1 11.0
Higher limit 2.0 V11,616 40.5 V14,796 31.8 8.2
Relative non-AAA related mortality of individual with AAA
Base case 1.11
Lower limit 1.0 V11,405 73.0 V14,515 57.3 15.4
Higher limit 3.0 V14,068 57.4 V17,844 45.3 12.0
All costs of AAA repair (OR þ EVAR)
Lower limit 0.5 V8,151 V10,371
Higher limit 2.0 V18,371 V23,375
Screening examination with ultrasound
Base case V16.45
Lower limit V10 V10,840 V13,793
Higher limit V40 V14,178 V18,041
Surveillance of AAA per year
Base case V117.8
Lower limit V50 V11,209 V14,262
Higher limit V250 V12,239 V15,572
Relative cost of surgery for rupture  cost of intact AAA surgery
Base case 1.62
Lower limit 1.3 V12,455 V15,847
Higher limit 3.0 V7,537 V9,590
Note. All effects and costs are discounted at 3.5% annually. ICER ¼ incremental cost-efﬁciency ratio; QALY ¼ quality-adjusted life-year;
ARR ¼ absolute risk reduction; AAA ¼ abdominal aortic aneurysm; OR ¼ open repair; EVAR ¼ endovascular aneurysm repair.
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deliver a reasonable clinical impact, in ARR per number of
individuals screened, to be justiﬁed. At approximately 9-year
follow-up the largest prostate cancer screening study re-
ported an ARR for disease-speciﬁc death of approximately
7.1 per 10,000 and a RRR of 20% from invitation to
screening.30 For breast cancer, the United States Preventive
Services Task Force and Cochrane reviews report ARR rates
of 5.3e6.8 and RRRs of 15e19%, respectively, at approxi-
mately 15 years of follow-up.31,32 Controversy seems to
surround interpretation of results of mammography
screening, as well as prostate cancer screening, and reports
of from zero to a much higher protective effect exist.33e35
For colorectal cancer, respective ARR rates of 8.5e20.0 and
RRRs of 16e31% are reported.36e38 Thus, modern AAA
screening of 65-year-old men (ARR¼ 15.1 and RRR¼ 42% at
13 years) seems to report competitive results in comparison.
Costs of primary screening and AAA surveillance differ
only slightly between the Swedish screening programmeand the MASS cost-efﬁciency report at 10 years,16 and also
affect the model outcome little (Table 4).
Recently published model studies reporting cost-
effectiveness of one-time screening of 65-year-old men
have employed base case prevalence rates of 3.3e8.9%.39e
41 These rates reﬂect international variations in AAA
occurrence,42 and are slightly higher than accumulating
data from the UK National Health Service screening pro-
gramme, reporting rates of 1.5%.12,43 A Dutch/Norwegian40
study reports base case ARR rates 5e6 times higher than
those in this study, but comparable ICERs in V/LY gained in
the long-term (V4,340/V9,860 compared with V5,783 in
this study). A Danish study41 reported the lowest base case
ICER in V/QALY gained of V685, which decreased to V437
in a sensitivity analysis with reduced prevalence (1.63%)
and reduced AAA growth rates. A comprehensive model of
one-time screening of 65-year-old men from the UK,
employing patient-level data from MASS at 4 years, pre-
dicted an ICER of V4,789/QALY gained at 30-year follow-up,
Figure 3. The incremental cost-efﬁciency ratio (ICER) in Euros per
quality-adjusted life-years (QALY) gained versus prevalence of
abdominal aortic aneurysm (AAA) at different degrees of incidental
detection and repair in the control cohort. Willingness-to-pay
threshold (horizontal dotted black line) was based on the cur-
rent National Institutes of Clinical Excellence value (£20,000
[V25,000]) per QALY gained. Follow-up is 13 years. All effects and
costs are discounted at 3.5% annually.
Table 5. Differences in key epidemiological and abdominal aortic
aneurysm (AAA)-related parameters between the model
(reﬂecting contemporary epidemiology) and the Multicentre
Aneurysm Screening Study (MASS). MASS data16 based on latest
available in-study cost-effectiveness analysis with 10 years of
follow-up cross-referenced with the model’s 10-year outcome in
base case. Life-years and costs are discounted at 3.5% annually.
Model MASS
Age (y)/strategy 65,
one-time
65e74,
one-time
Follow-up (y) 10 10
Mean age at
time of screening (y)
65 69.2
General life-expectancy
of a 65-year-old man
18.51b 15.19c
Prevalence of AAA
in 65-year-old men
1.7% 3.5%d
Proportion EVAR 50% 12.8%
30-d mortality,
OR for intact AAA
Reference 1.92
Non-AAA-related,
relative risk reduction
in mortality in invited cohorta
0.53% 0.53%
ARR for death from
AAA per 10,000 invited
13.4 41.6
NNS to prevent
one death from AAA
597 192
RRR, death from AAA 49% 48%
Life-years gained with
invitation to screening
per 10,000 invited
46.7 131.5
Life-years gained for
each prevented
death from AAA
3.5 3.2
Incremental cost-efﬁciency
ratio (V/life-year gained),
invited vs. control
18,552 10,139
Note. EVAR ¼ endovascular aneurysm repair; OR ¼ open repair;
ARR ¼ absolute risk reduction; NNS ¼ numbers needed to treat;
RRR ¼ relative risk reduction.
a Non-AAA related relative risk reduction in mortality calculated
from 13-year data in MASS.
b Based on population statistics from Sweden 2012.20
c Based on population statistics from UK in 1998, estimated
midpoint of inclusion in MASS.47
d Data from Collaborative Aneurysm Screening Study Group,
2001.46
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the 65-year-old men.39
Although the surgical management and prevalence rate
in MASS could be argued to be out of date, the growth
rate and natural history of an AAA has not changed over
time, as suggested by the work of Sweeting et al.44 This
supports the basing of our model on the extracted natural
history of AAAs in MASS while testing the effect of modern
epidemiology on AAA screening. In essence, this is done by
substituting the parameters that have changed since the
start of the MASS trial, with data that reﬂect contempo-
rary epidemiology. This includes a lower AAA prevalence
than in the MASS trial, decreased peri-operative mortality,
and increased longevity of the population.8,21 A novel
component in the model was to include the degree of
incidental detection and repair of AAAs in the sensitivity
analysis.
Cardiovascular risk factor proﬁles in Western societies are
improving and basing non-AAA-related relative mortality of
men with AAA on recently reported long-term survival of
AAA patients ensures that this effect is included in the
simulation.21
This study has several limitations. The rate of acceptance
for surgery reﬂects those of the MASS study population. It is
likely that, owing to the introduction of EVAR, a higher
proportion of individuals with large AAAs are offered sur-
gery nowadays. Variations in this parameter are difﬁcult to
simulate in our model, and the effect of increased repair
rates for intact AAA would be especially evident in the
invited group, and may underestimate the current protec-
tive effect of screening.
In the MASS trial cause of death was based on non-
validated International Classiﬁcation of Disease codes.
Thus, death due to rupture of an unknown AAA could likely
be misclassiﬁed as due to ischaemic heart disease, and
death due to ischaemic heart disease in a person with asmall AAA could be misclassiﬁed as due to rupture. Such
misclassiﬁcation could cause a limited bias towards cost-
ineffectiveness.
AAA progression was based on observed rates in MASS
up to 13 years. Progression rates beyond that are specula-
tive. However, the lifetime estimates in this model are made
by analysis of survival data and data from the Swedvasc
registry, where virtually no repairs of AAA occur after 90
years of age, and virtually no individuals with AAA survive
beyond 95 years of age.
A probabilistic sensitivity analysis has not been con-
ducted. Several of the parameters in the model are
dependent on time of follow-up and the age of the
364 S. Svensjö et al.individual, and not easily described concerning statistical
distribution. For some parameters there is a lack of any type
of information on distribution characteristics. The distribu-
tion of the costs of AAA repair is clearly described in the
study they were based on, but cost of AAA repair had little
effect on the outcome.26 It was judged that basing a
probabilistic sensitivity analysis on only one or two pa-
rameters with known distributions was not appropriate, and
would add little value to the analysis. Furthermore, varia-
tion in attendance has been tested in a previous model,45
and was found to have virtually no effect on cost-
efﬁciency. In addition, multiple screening reports have dis-
played stable attendance rates at approximately 80%.
Therefore, this parameter was not explored in the sensi-
tivity analysis.
CONCLUSION
AAA screening of 65-year-old men appears to remain a cost-
efﬁcient and effective healthcare intervention within the
framework of modern epidemiology and management.
However, continued close monitoring of the costs and
impact of such programmes is highly relevant in view of the
dramatic changes in AAA epidemiology and management
that has been observed during the last decade.
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